Merck to phase out osteoporosis specialty team

Share this article:

Merck plans to eliminate its osteoporosis specialty team at the end of the year, ahead of the February 2008 patent expiration of its bone density blockbuster Fosamax.

A total of 250 positions from the osteoporosis team, including some sales jobs, will be impacted, according to Merck spokeswoman Amy Rose.

“We informed this group of individuals well in advance so that we could work with them to find other opportunities within Merck that fit their skills and interest,” Rose told MM&M.

Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.